All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Ropeg alfa-2b on JAK2V617F allele burden, molecular response, and EFS in early PV

Jul 1, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in polycythemia vera.

During the European Hematology Association Hybrid Congress 2024, Jean-Jacques Kiladjian delivered a presentation on the correlation between JAK2V617F molecular response (MR) and event-free survival (EFS) in early polycythemia vera (PV).1 The final data from the phase III PROUD-PV and CONTINUATION-PV trials were used to assess this correlation, as well as the impact of ropeginterferon (ropeg) alfa-2b on EFS.1

Key learnings1

The probability of EFS during the study periods was significantly higher in patients who experienced a MR at a hazard ratio (HR) of 0.24 (95% confidence interval [CI], 0.07–0.83; p = 0.02).

Time spent in MR was higher in patients treated with ropeg alfa-2b compared with hydroxyurea or best available therapy (BAT) at 66.7% vs 8.4%, respectively (p = 0.01).

A higher JAK2V617F allele burden was associated with an increased risk of events at an HR of 1.042 (95% CI, 1.023–1.062; p = 0.0001), equating to 4.2% increased risk of events per 1% increase in variant allele frequencies.

Treatment with ropeg alfa-2b was associated with higher rates of <1% JAK2V617F allele burden, achieved in 20.7% of patients compared with 1.4% in the control arm (p = 0.0001).

These data suggest that a 10% decrease in allele burden could correspond with a 34% decreased risk of events.

Overall, findings from these trials suggest that there is a correlation between MR and EFS, as well as JAK2V617F and EFS, both of which could be extended with the use of ropeg alfa-2b. 

  1. Kiladjian JJ. JAK2V617F molecular response correlates with event-free survival in an early polycythemia vera population. Oral Abstract #S219. Presented at: EHA Hybrid Congress; Jun 15, 2024; Madrid, ES.


Subscribe to get the best content related to MPN delivered to your inbox